Skip to main content
Premium Trial:

Request an Annual Quote

MP Biomedicals Asia Pacific, A*STAR Partner on Coronavirus Point-of-Care Assay

NEW YORK — MP Biomedicals Asia Pacific said on Friday that it partnered with Singapore's Agency for Science, Technology and Research (A*STAR) to develop a point-of-care antibody test for SARS-CoV-2.

Called Assure, the lateral flow-based immunoassay is designed to detect immunoglobulin G and M antibodies against SARS-CoV-2 in human blood, plasma, and serum, and provides results within 15 minutes, according to Singapore-based MP Biomedicals Asia Pacific.

The company said that Assure has received provisional authorization from Singapore regulators and that it is currently being distributed in Europe, Africa, and South America. MP Biomedicals Asia Pacific added that it plans to submit the test for Emergency Use Authorization from the US Food and Drug Administration.

MP Biomedicals Asia Pacific is a subsidiary of Irvine, California-based MP Biomedicals.

In March, A*STAR received provisional authorization in Singapore for an RT-PCR-based SARS-CoV-2 assay developed with Tan Tock Seng Hospital.